Cenersen

Drug Profile

Cenersen

Alternative Names: Aezea; Cenersen sodium; EL625; EL831; OL(1)p53

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Nebraska Medical Center
  • Developer Eleos; H. Lee Moffitt Cancer Center and Research Institute
  • Class Antineoplastics; Antisense oligonucleotides
  • Mechanism of Action Tumour suppressor protein p53 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia; Chronic lymphocytic leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Myelodysplastic syndromes
  • Discontinued Acute myeloid leukaemia; Chronic lymphocytic leukaemia

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Myelodysplastic-syndromes in USA (IV, Infusion)
  • 01 Sep 2014 Phase-I clinical trials in Myelodysplastic syndromes in USA (IV)
  • 18 Jul 2012 Discontinued - Phase-II for Acute myeloid leukaemia in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top